
Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) – Stock analysts at Zacks Research decreased their FY2026 earnings per share estimates for shares of Gilead Sciences in a research note issued on Thursday, November 12th. Zacks Research analyst Team now forecasts that the biopharmaceutical company will earn ($0.86) per share for the year, down from their prior estimate of ($0.65). Zacks Research has a “Hold” rating on the stock. The consensus estimate for Gilead Sciences’ current full-year earnings is ($0.97) per share. Zacks Research also issued estimates for Gilead Sciences’ Q4 2026 earnings at $1.31 EPS, Q4 2027 earnings at $2.58 EPS and Q1 2028 earnings at $2.16 EPS.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.19 by $0.36. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. The business had revenue of $8.30 billion during the quarter, compared to the consensus estimate of $7.81 billion. During the same quarter last year, the firm posted $2.47 EPS. The company’s quarterly revenue was up 6.8% on a year-over-year basis.
Several other analysts also recently commented on GILD. Argus set a $190.00 target price on shares of Gilead Sciences in a report on Thursday, November 12th. HSBC upped their price target on shares of Gilead Sciences from $155.00 to $175.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. Wall Street Zen raised shares of Gilead Sciences from a “hold” rating to a “buy” rating in a report on Saturday, September 19th. Citigroup raised their price objective on shares of Gilead Sciences from $165.00 to $188.00 and gave the stock a “buy” rating in a research report on Friday, October 30th. Finally, Weiss Ratings upgraded shares of Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, September 14th. Twenty-three equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $171.63.
View Our Latest Research Report on GILD
Gilead Sciences Stock Up 1.6%
Shares of GILD opened at $170.26 on Monday. The company’s 50-day moving average is $155.90 and its 200-day moving average is $142.09. Gilead Sciences has a fifty-two week low of $116.88 and a fifty-two week high of $176.58. The company has a debt-to-equity ratio of 1.84, a current ratio of 1.38 and a quick ratio of 1.22.
Institutional Trading of Gilead Sciences
Large investors have recently modified their holdings of the stock. Persistent Asset Partners Ltd bought a new stake in shares of Gilead Sciences during the second quarter valued at about $25,000. Kimelman & Baird LLC purchased a new stake in shares of Gilead Sciences in the second quarter worth about $25,000. PFS Partners LLC lifted its holdings in shares of Gilead Sciences by 101.1% in the third quarter. PFS Partners LLC now owns 191 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 96 shares in the last quarter. Raffa Wealth Management LLC purchased a new stake in shares of Gilead Sciences in the third quarter worth about $28,000. Finally, Laurel Wealth Advisors LLC bought a new position in shares of Gilead Sciences in the third quarter valued at approximately $29,000. 83.67% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling
In related news, CFO Andrew Dickinson sold 3,000 shares of the stock in a transaction that occurred on Monday, November 16th. The stock was sold at an average price of $171.47, for a total transaction of $514,410.00. Following the sale, the chief financial officer owned 158,096 shares of the company’s stock, valued at $27,108,721.12. This represents a 1.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel O’Day sold 9,810 shares of the stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $175.17, for a total value of $1,718,417.70. Following the sale, the chief executive officer directly owned 551,683 shares in the company, valued at $96,638,311.11. This represents a 1.75% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 242,709 shares of company stock valued at $40,524,237. 0.30% of the stock is currently owned by corporate insiders.
Gilead Sciences Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be paid a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 1.9%. The ex-dividend date is Tuesday, December 15th. Gilead Sciences’s payout ratio is -103.80%.
More Gilead Sciences News
Investors following GILD have been watching these news items:
- Positive Sentiment: Gilead signed royalty-free licenses with three generic manufacturers to support potential future access to investigational Ebola drug obeldesivir in 127 countries. The initiative expands access if the drug is authorized, but is unlikely to generate meaningful near-term sales while it remains experimental. Reuters: Gilead signs generic licensing deals for experimental Ebola drug
- Neutral Sentiment: Gilead executives appeared at the Jefferies and UBS healthcare conferences, but the provided headlines do not identify specific new guidance or announcements that would change the investment outlook. Jefferies conference transcript
- Negative Sentiment: A separate report said Zacks Research forecast lower earnings, adding a cautious estimate revision to the mix. Zacks earnings forecast
Gilead Sciences Company Profile
Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.
Featured Articles
- Five stocks we like better than Gilead Sciences
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
